The inner material of soft plaque becomes visible to blood when it ruptures, which causes platelets and clotting factors to bind to it. This can lead to a sudden blood clot that blocks the artery, ...
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...